Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung ade-nocarcinoma. Materials and Methods Patients (n=176) with oligometastatic lung adenocarcinoma treated with LART were identified, and those treated with LART at the initial diagnosis of synchronous oligometastatic disease (OMD group) or treated with LART when they presented with repeat oligoprogression (OPD group) were included. Results In the OMD group (n=54), the 1- and 3-year progression-free survival (PFS) were 50.9% and 22.5%, respectively, whereas the 1- and 3-year overall survival in the OPD group were 75.9% and 58.1%, respectively. Forty-one patients (75.9%) received LART at all gross disease sites. Tyrosine kinase inhibitor (TKI) use and all-metastatic site LART were significant predictors of higher PFS (p=0.018 and p=0.046, respectively). In patients treated with TKIs at the time of LART (n=23) and those treated with all-metastatic site LART, the 1-year PFS was 86.7%, while that of patients not treated with all-metastatic site LART was 37.5% (p=0.006). In the OPD group (n=122), 67.2% of the patients (n=82) maintained a systemic therapy regimen after LART. The cumulative incidence of changing systemic therapy was 39.6%, 62.9%, and 78.5% at 6 months, 1 year, and 2 years after LART, respectively. Conclusion Aggressive LART can be an option to improve survival in patients with oligometastatic disease. Patients with synchronous oligometastatic disease receiving TKI and all-metastatic site LART may have improved PFS. In patients with repeat oligoprogression, LART might potentially extend survival by delaying the need to change the systemic treatment regimen.
Abstract
Purpose This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung ade-nocarcinoma. Materials and Methods Patients (n=176) with oligometastatic lung adenocarcinoma treated with LART were identified, and those treated with LART at the initial diagnosis of synchronous oligometastatic disease (OMD group) or treated with LART when they presented with repeat oligoprogression (OPD group) were included. Results In the OMD group (n=54), the 1- and 3-year progression-free survival (PFS) were 50.9% and 22.5%, respectively, whereas the 1- and 3-year overall survival in the OPD group were 75.9% and 58.1%, respectively. Forty-one patients (75.9%) received LART at all gross disease sites. Tyrosine kinase inhibitor (TKI) use and all-metastatic site LART were significant predictors of higher PFS (p=0.018 and p=0.046, respectively). In patients treated with TKIs at the time of LART (n=23) and those treated with all-metastatic site LART, the 1-year PFS was 86.7%, while that of patients not treated with all-metastatic site LART was 37.5% (p=0.006). In the OPD group (n=122), 67.2% of the patients (n=82) maintained a systemic therapy regimen after LART. The cumulative incidence of changing systemic therapy was 39.6%, 62.9%, and 78.5% at 6 months, 1 year, and 2 years after LART, respectively. Conclusion Aggressive LART can be an option to improve survival in patients with oligometastatic disease. Patients with synchronous oligometastatic disease receiving TKI and all-metastatic site LART may have improved PFS. In patients with repeat oligoprogression, LART might potentially extend survival by delaying the need to change the systemic treatment regimen.
참고문헌 (33)
- Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
- Casiraghi M, "A 10-year single-center experience on 708lung metastasectomies : the evidence of the"international registry of lung metastases"", J Thorac Oncol, 6, pp.1373~1378 (2011)
- Aitken K, "Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases : can we change the therapeutic paradigm?", Clin Oncol(R Coll Radiol), 27, pp.411~419 (2015)
- Milano MT, "Oligometasta ses treated with stereotactic body radiotherapy : long-term follow-up of prospective study", Int J Radiat Oncol Biol Phys, 83, pp.878~886 (2012)
- Rim CH, "Role of Local treatment for oligometastasis : a comparability based meta-analysis", Cancer Res Treat, 54, pp.953~969 (2022)
- Kroese TE, "Definition of oligometa static esophagogastric cancer and impact of local oligometas tasis-directed treatment : a systematic review and meta-anal ysis", Eur J Cancer, 166, pp.254~269 (2022)
- Gutiontov SI, "(Oligo)metastasis as a spectrum of disease", Cancer Res, 81, pp.257783~ (2021)
- Iyengar P, "Consolidative radiotherapy for limited metastatic non-small-cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 4, pp.e173501~ (2018)
- Gomez DR, "Local consolidative therapy vs. maintenance therapy or observation for patients with oligo metastatic non-small-cell lung cancer : long-term results of a multi-institutional, phase II, randomized study", J Clin Oncol, 37, pp.1558~1565 (2019)
- Palma DA, "Stereotactic ablative radiotherapy for the comprehen sive treatment of oligometastatic cancers : long-term results of the SABR-COMET phase II randomized trial", J Clin Oncol, 38, pp.2830~2838 (2020)
- Cheung P, "Stereotactic body radiotherapy for oligoprogres sive cancer", Br J Radiol, 89, pp.20160251~ (2016)
- Guckenberger M, "Characterisation and classification of oligometastatic disease : a European Society for Radiothera py and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation", Lancet Oncol, 21, pp.e18~e28 (2020)
- Patel PH, "The Dandelion dilemma revisited for oligoprogression : treat the whole lawn or weed selectively?", Clin Oncol(R Coll Radiol), 31, pp.824~833 (2019)
- Tree AC, "Stereotactic body radiotherapy for oligometas tases", Lancet Oncol, 14, pp.e28~e37 (2013)
- Lievens Y, "Defining oligometastatic disease from a radi ation oncology perspective : an ESTRO-ASTRO consensus document", Radiother Oncol, 148, pp.157~166 (2020)
- Lazzari R, "Stereotactic body radiation therapy for oligometastatic ovarian cancer : a step toward a drug holiday", Int J Radiat Oncol Biol Phys, 101, pp.650~660 (2018)
- Merino Lara T, "Multisite stereotactic body radiotherapy for meta static non-small-cell lung cancer : delaying the need to start or change systemic therapy?", Lung Cancer, 124, pp.219~226 (2018)
- Santini D, "Outcome of oligoprogressing metastatic renal cell car cinoma patients treated with locoregional therapy : a multi center retrospective analysis", Oncotarget, 8, pp.100708~100716 (2017)
- Pembroke CA, "Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression", Radiother Oncol, 127, pp.493~500 (2018)
- Triggiani L, "Efficacy of stereotactic body radiotherapy in oligorecur rent and in oligoprogressive prostate cancer : new evidence from a multicentric study", Br J Cancer, 116, pp.1520~1525 (2017)
- Sutera P, "Initial results of a multicenter phase 2 trial of stereo tactic ablative radiation therapy for oligometastatic cancer", Int J Radiat Oncol Biol Phys, 103, pp.116~122 (2019)
- Lin JJ, "Five-year survival in EGFR-mutant meta static lung adenocarcinoma treated with EGFR-TKIs", J Thorac Oncol, 11, pp.556~565 (2016)
- Charloux A, "The increasing incidence of lung adenocarcinoma : reality or artefact? : a review of the epidemiology of lung adenocarci noma", Int J Epidemiol, 26, pp.14~23 (1997)
- Mitchell KG, "Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer", Clin Lung Cancer, 21, pp.37~46 (2020)
- Gomez DR, "Local consolidative therapy versus main tenance therapy or observation for patients with oligometa static non-small-cell lung cancer without progression after f irst-line systemic therapy : a multicentre, randomised, con trolled, phase 2 study", Lancet Oncol, 17, pp.1672~1682 (2016)
- Ruers T, "Local treatment of unresectable colorec tal liver metastases : results of a randomized phase II trial", J Natl Cancer Inst, 109, pp.djx015~ (2017)
- Shirvani SM, "Biology-guided radiotherapy : redefining the role of radiotherapy in metastatic cancer", Br J Radiol, 94, pp.20200873~ (2021)
- Bauml JM, "Pembrolizumab after completion of locally ablative ther apy for oligometastatic non-small cell lung cancer : a phase 2trial", JAMA Oncol, 5, pp.1283~1290 (2019)
- Gan GN, "Stereotactic radiation therapy can safe ly and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase positive lung cancer patients receiving crizotinib", Int J Radiat Oncol Biol Phys, 88, pp.892~898 (2014)
- Thompson R, "Outcomes of extra-cranial stereotactic body radio therapy for metastatic colorectal cancer : dose and site of meta stases matter", Radiother Oncol, 142, pp.236~245 (2020)
- Farooqi A, "Increased biologically effective dose(BED)to the pri mary tumor is associated with improved survival in patients with oligometastatic NSCLC", Radiother Oncol, 163, pp.114~118 (2021)
- Onishi H, "Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma : clinical outcomes in 245subjects in a Japanese multiinstitutional study", Cancer, 101, pp.1623~1631 (2004)
- Moreno AC, "Biologically effective dose in stereotactic body radio therapy and survival for patients with early-stage NSCLC", J Thorac Oncol, 15, pp.101~109 (2020)